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Background: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a het-
erogeneous group of inﬂammatory demyelinating diseases of the central nervous system, usually responsive to
conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is
scarce.
Methods: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-
induced B-cell depletion.
Results: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on
MRI, and a remarkable reduction of disability at the two-year follow-up.
Conclusion: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as
an option for the treatment of MOG-SD.
Myelin oligodendrocyte glycoprotein (MOG) antibody-related
spectrum disorders (MOG-SD) are a phenotypically heterogeneous
group of diseases that include optic neuritis, myelitis, brainstem en-
cephalitis, and acute disseminated encephalomyelitis (ADEM)-like
presentations. MOG-SD can be considered a disease entity distinct from
multiple sclerosis (MS) and aquaporin-4 (AQP4)-antibody-positive
neuromyelitis optica spectrum disorders1.
In analogy with AQP4 antibody-positive NMOSD, therapies ap-
proved for MS can be ineﬀective or even harmful in MOG-SD
(Jarius et al., 2018). Patients with NMOSD refractory to ﬁrst-line con-
ventional drugs (e.g., rituximab and azathioprine) can beneﬁt from
treatments with the interleukin-6 receptor (IL-6r) blocking monoclonal
antibody tocilizumab (TCZ) (Trebst et al., 2014). Three studies showed
the potential eﬃcacy of TCZ in small groups of highly relapsing, and
mainly AQP4 antibody-positive NMOSD patients who were un-
responsive to conventional therapies (Ayzenberg et al., 2013;
Araki et al., 2014; Ringelstein et al., 2015).
We report on the ﬁrst patient with highly active and rituximab-
unresponsive MOG-SD who was treated with TCZ.
In August 2015, a 20-year-old male without any relevant medical
history, developed right eye visual impairment that rapidly involved
the fellow eye. Neurological examination showed only visual dis-
turbances, with a visual acuity of 20/25 in both eyes. Brain MRI dis-
closed unremarkable results and a bilateral optic neuritis was diag-
nosed. The patient was treated with oral prednisone (50mg/day halved
every 10 days) for 1 month, with normalization of visual acuity. In
October 2015, the patient came to our attention after developing lower
limbs sensory deﬁcits with urinary retention. Neurological examination
showed a left side hemiparesis with tetra-hyperreﬂexia, upper limbs
hypopallesthesia, and abdominal hyperesthesia (T8 sensory level).
Spinal MRI showed non-enhancing, longitudinal, and thin T2 hyper-
intense lesions involving T4-T6, T8-T10, and T12-L1 segments (Fig. 1A)
with lumbar leptomeningeal Gadolinium (Gd) enhancement. CSF ana-
lysis disclosed normal cell count and total protein concentration, and
identical oligoclonal IgG bands in serum and CSF (mirror pattern). In-
fectious myelitis was excluded on the ground of serologic and virologic
CSF results. Serum anti-nuclear antibodies, anti-extractable nuclear
antigens, and AQP4 antibodies tested negative, whereas MOG
https://doi.org/10.1016/j.msard.2018.11.012
Received 28 September 2018; Received in revised form 11 November 2018; Accepted 12 November 2018
⁎ Corresponding author at: Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa,
Clinica neurologica, Largo Paolo Daneo3, Genoa 16132, Italy.
E-mail addresses: giovanninovi@gmail.com (G. Novi), matteo.gastaldi@mondino.it (M. Gastaldi), diego.franciotta@mondino.it (D. Franciotta),
pescegpl@unige.it (G. Pesce), luanabenedetti@libero.it (L. Benedetti), auccelli@neurologia.unige.it (A. Uccelli).
1 These senior authors equally contributed to the manuscript.
Multiple Sclerosis and Related Disorders 27 (2019) 312–314
2211-0348/ © 2018 Published by Elsevier B.V.
T
antibodies were positive for both total IgG and IgG1 (in-house cell-
based assays, using HEK293T cells transfected with human full-length
MOG). A diagnosis of MOG-SD was made and the patient was treated
with high-dose intravenous steroids (1 g 6-methylprednisolone/day for
5 days), with partial improvement of symptoms. In December 2015, a
sensory relapse occurred. Spinal MRI showed two new Gd enhancing
lesions involving C5 and T5 segments (Fig. 1B). High-dose intravenous
steroids were administered, with symptoms resolution. The patient then
underwent two rituximab cycles (1 g/infusion, 15 days apart) in Jan-
uary 2016. Despite a complete B-cell depletion, two relapses occurred,
manifesting as cervical myelitis (Fig. 1C), and as right eye optic neur-
itis, respectively at 3 and 5 months after rituximab induction. There-
fore, in September 2016, treatment with TCZ (8mg/kg every 4 weeks)
was initiated. At 24-month follow-up, no new relapses had occurred,
and the patient was substantially asymptomatic (only lower limbs hy-
perreﬂexia at neurological examination). Spinal MRI showed a reduc-
tion of cervical and thoracic lesions (Fig. 1D). Serial serum MOG anti-
body determinations, performed every 6 months, showed the
persistence of high antibody titers (Fig. 1; median value: 1:18,740;
range: 1:17,280–1:40,000). No adverse events occurred throughout the
TCZ therapy, still ongoing (Ringelstein et al., 2015).
This case suggests that TCZ can be an eﬀective therapeutic option in
rituximab refractory MOG-SD. The mechanisms of action underlying
the eﬀects of TCZ in our MOG-SD patients are not known but may
suggest diﬀerent pathogenic mechanisms between MOG-SD and
NMOSD. Both AQP4 and MOG antibody-associated disorders seem to
share similar cytokine signatures, characterized by higher CSF IL-6
concentrations vs. MS patients and healthy controls (Kaneko et al.,
2018). IL-6 has a crucial role in promoting the survival of circulating
plasmablasts, a major source of AQP4 antibodies in NMOSD
(Chihara et al., 2011). In addition, IL-6 levels are increased in serum
and CSF samples during NMOSD relapses (Uzawa et al., 2010), and
responses to TCZ in rituximab unresponsive AQP4 antibody-positive
NMOSD have been reported (Ayzenberg et al., 2013; Araki et al., 2014;
Ringelstein et al., 2015).
The persistence of high MOG antibody titers in our patient despite
the clinico-radiologic improvements suggest that they could be a bio-
marker of disease, but not of response to therapy, and further stimulates
the debate about whether human MOG-antibodies are pathogenic or
epiphenomenic. A further clue favoring the epiphenomenic hypothesis
comes from the post-TCZ reduction of spinal cord lesions observed in
our patient, in contrast with what suggested by the complement-
mediated pathogenic eﬀects of a subset of MOG antibodies in an animal
model (Marignier et al., 2017), and with what observed in AQP4 an-
tibody-positive NMOSD (Marignier et al., 2017).
Further studies on TCZ-treated MOG-SD patients, with and without
preceding rituximab cycles, should be performed to conﬁrm our ob-
servations. If conﬁrmed by other studies, TCZ should be considered as a
possible option to treat NMOSD individuals regardless of the pheno-
typic presentations.
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